Giant Biotech (02367.HK) Hot Stock Analysis Report

Giant Biotech (02367.HK) is a consumer defensive sector enterprise focusing on recombinant collagen technology [0]. Its closing price on January 2, 2026, was HK$34.220, with a decrease of 0.36% [0]. The company has recently become a hot stock in Hong Kong, mainly driven by three catalysts:

1. Institutional Rating Adjustment
   : China Merchants Securities International downgraded its rating from “Overweight” to “Neutral”, and the target price was sharply reduced by 45% from HK$64 to HK$35, citing the company’s reputation crisis and double-digit sales decline of its core brand “Kefumei” during Double 11 [1][2].
2. Share Repurchase Behavior
   : Since December 9, the company has repurchased a total of 4.8 million shares, with a single-day repurchase of 400,000 shares on December 29 at a price range of HK$34.28-HK$34.76, indicating management’s recognition of the current stock price [3].
3. Overseas Technology Layout
   : It signed a strategic cooperation agreement with Sweden’s Nordberg Medical, granting it the rights to develop, produce, and commercialize recombinant collagen technology in global markets (excluding mainland China), opening up international market space [4].

In terms of price and trading volume, the trading volume on December 31 was 4,668,830 shares, significantly lower than the average trading volume of 11,620,134 shares in the past three months, indicating light trading [5]; the current stock price is in the low range of the 52-week interval of HK$33.000-HK$87.100 [5].

1. Intertwined Dual Sentiments
   : The institutional rating downgrade has triggered market caution about short-term growth, while share repurchases and overseas layout have brought long-term value expectations, leading to分化 in market sentiment.
2. Valuation and Expectation Gap
   : Although the company’s price-to-earnings ratio (TTM) is 13.53 [5], which is at a low level, the institutional expectation downgrade may lead to further valuation adjustments, requiring attention to signs of stabilization in subsequent sales data.
3. Strategic Significance of Overseas Technology
   : The cooperation with Nordberg Medical is an important step in the internationalization of the company’s technology. If successfully implemented, it will open a new growth curve for the company, but short-term progress needs to be observed.

• Risk Points
  : The sales decline and reputation crisis of core brands may continue to affect short-term performance; market consensus expectations may further adjust after institutional rating downgrades; overseas technology cooperation faces execution risks of integration and market expansion.
• Opportunity Window
  : Share repurchases show the company’s confidence in long-term value, which may attract value investors; overseas technology layout brings long-term growth imagination space in international markets.

Giant Biotech has recently become a hot stock in Hong Kong due to institutional rating adjustments, share repurchases, and overseas technology cooperation. The current stock price is at a 52-week low with light trading. Although it faces slowing growth and valuation pressure in the short term, repurchase behavior and overseas layout provide support for long-term development. Investors need to pay attention to subsequent sales data, cooperation progress, and changes in market sentiment to make decisions based on their own risk preferences.